explore -WSS

explore

author：knowledge 2025-09-27 23:53:52 - browse：5796

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

explore

leisure time

focus

WSS

Cue Health, Covid

Digital health: a case of mistaken identity

Making the case for fair compensation in clinical trials

Study finds gene variants tied to breast cancer risk in Black women

Investigation reveals sickle cell patients pressured into sterilizations

Listen: More tumult at BIO & coercive care for sickle cell patients

knowledge

explore

Lobbying power of AI, software-enabled devices

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

ASCO eve: Let’s set the table for this year's meeting

Trump demands the U.S. pay no more for drugs than other countries … again

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Medical records are filled with copy

The Pandemic Treaty must support building strong health systems

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

The cancer drug shortage isn’t new — and neither are the solutions

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

entertainment

ASCO: Palliative care found as helpful given virtually as in person

H5N1 virus can be tracked in retail milk, scientists say

Making the case for fair compensation in clinical trials

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

UnitedHealth argues against case alleging wrongful AI care denials

At flashy new research hub, AstraZeneca lays out ambitious growth goals

explore

leisure time

focus

focus